Mutations in mitochondrial (mt) genes coding for mt-tRNAs are responsible for a range of syndromes, for which no effective treatment is available. We recently showed that the carboxy-terminal domain (Cterm) of human mt-leucyl tRNA synthetase rescues the pathologic phenotype associated either with the m.3243A>G mutation in mt-tRNA Leu(UUR) or with mutations in the mt-tRNA Ile , both of which are aminoacylated by Class I mt-aminoacyl-tRNA synthetases (mt-aaRSs). Here we show, by using the human transmitochondrial cybrid model, that the Cterm is also able to improve the phenotype caused by the m.8344A>G mutation in mt-tRNA Lys , aminoacylated by a Class II aaRS. Importantly, we demonstrate that the same rescuing ability is retained by two Cterm-derived short peptides, β30_31 and β32_33, which are effective towards both the m.8344A>G and the m.3243A>G mutations. Furthermore, we provide in vitro evidence that these peptides bind with high affinity wild-type and mutant human mt-tRNA Leu(UUR) and mt-tRNA Lys , and stabilize mutant mt-tRNA Leu(UUR) .
Introduction
Mitochondrial (mt) diseases are multi-system disorders due to mutations in nuclear or mtDNA genes. Among the latter, >50% are located in transfer RNA (tRNA) genes [(1); URL: http://www. mitomap.org] and are responsible for a wide range of clinical phenotypes, such as the severe Mitochondrial Encephalopathy with Lactic Acidosis and Stroke like Episodes (MELAS) and Myoclonic Epilepsy with Ragged-Red Fibres (MERRF) syndromes, for which no effective treatments are available at present (2) .
Evidence provided by our group and others has shown that overexpression of mt-aminoacyl-tRNA synthetases (mt-aaRSs) attenuates the detrimental effects of point mutations in cognate mt-tRNAs both in human cells (3) (4) (5) (6) and in a yeast model (7, 8) . Our group and others extended these results by showing that class Ia human mt-leucyl-tRNA synthetase (mt-LeuRS) and mtvalyl-tRNA synthetase (mt-ValRS) are able to rescue defects due to pathogenic mutations in non-cognate, as well as cognate, mttRNAs, in both human transmitochondrial cybrid cells (herein named cybrids) (9, 10) and yeast (11) .
We further demonstrated that the rescuing activity of human mt-LeuRS resides in a relatively small (<70 amino acids) protein region: the carboxy-terminal domain (Cterm) (9, 10) . Cterm overexpression in human cybrids rescued both relatively mild defects caused by two different homoplasmic mutations in the noncognate mt-tRNA Ile gene (MTTI), and severe pathological phenotypes caused by the heteroplasmic m.3243A>G mutation in the cognate mt-tRNA Leu(UUR) gene (MTTL1) (9) . The latter mutation is the most prevalent heteroplasmic mt-tRNA mutation associated with mt disease, leading to a wide spectrum of clinical manifestations. These are partly determined by the level of heteroplasmy and include maternally inherited diabetes and deafness and the severe biochemical and clinical phenotypes ascribed to MELAS (12, 13) . We showed that the Cterm is both necessary and sufficient for the entire rescuing activity. It is more effective than the full-length enzyme on all mtDNA mutations tested, whereas the activity of a mt-LeuRS variant deleted of the Cterm is negligible or missing (9) . We proposed that the Cterm rescuing activity is mediated by a chaperone-like mechanism: the Cterm would directly interact with the mutated mt-tRNAs and stabilize a conformation suitable to establish interactions with cognate aaRS, or other molecular partners required to perform tRNA function. This hypothesis is supported by in vitro experiments demonstrating that the Cterm directly interacts with both the cognate human mt-tRNA Leu(UUR) , with high affinity and stability, and with the non-cognate human mttRNA Ile , although with lower affinity (9) .
To identify the minimal Cterm regions responsible for the rescue, we designed short peptides comprising the Cterm regions that interact with tRNA Leu in the available three-dimensional (3D) structures (14, 15) . These peptides were named β30_31 (15 aa) and β32_33 (16 aa), since they encompass β-strands 30 and 31, and β-strands 32 and 33, respectively. Both peptides were endowed with even higher rescuing activity than the full Cterm when directed to a large panel of yeast mt-tRNA mutants (16, 17) . In the work here presented, we have investigated the rescuing ability of β30_31 and β32_33 peptides in human cybrids bearing either the aforementioned m.3243A>G mutation in MTTL1, or the m.8344A>G MERRF mutation in mt-tRNA Lys (MTTK). Both peptides are able to ameliorate viability and energetic proficiency of human cells carrying either mutation and to interact in vitro with mutant human mt-tRNA Leu(UUR) and mt-tRNA Lys . In the case of the 'cognate' mt-tRNA Leu(UUR) m.3243A>G mutant, both peptides also restore wild-type (WT) levels of thermal stability and structure, which are strongly impaired by the mutations. These results indicate that β30_31 and β32_33 peptides, derived from the Cterm fragment of mt-LeuRS, are new tools to effectively correct defective phenotypes caused by mutations in mt-tRNA genes. Hence, they represent attractive lead molecules for the development of compounds aimed at therapeutic applications against syndromes associated with pathogenic mt-tRNA mutations. Fig. S1D ).
Results
The carboxy-terminal domain of human mt-LeuRS is able to rescue the phenotype of m.8344A>G MTTK mutant cybrids
We transiently expressed the Cterm in H-8344 and L-8344 cybrids. This resulted in increased cell viability of H-8344 cybrids after 24 h incubation in galactose medium (up to 1.5-fold as compared to mock transformants) and decreased apoptosis after 6 h (up to 1.6-fold when compared with mock transformants) ( Fig. 1A and B). Moreover, Cterm transformants showed a significant increase in oxygen consumption when compared with mock transformants (up to 1.4-fold increase) (Fig. 1C) . Conversely, Cterm overexpression did not affect viability of isogenic L-8344 cybrids ( Fig. 1A and C) . For each experiment, we measured transfection efficiency by quantitative real-time polymerase chain reaction (PCR) (Fig. 1D ).
Cterm-derived peptides are endowed with rescuing ability towards both m.3243A>G MTTL1 and m.8344A>G MTTK mutant cybrid phenotypes
The structural basis of the interaction between the Cterm of human mt-LeuRS and the cognate tRNA can be inferred from the analysis of the experimentally determined 3D structures of LeuRS-tRNA Leu complexes from the bacteria Thermus thermophilus (14) and Escherichia coli (15) available from the Protein Data Bank [PDB; (18) ]. As shown in Figure 2 , two pairs of β-strands in the carboxy-terminal domain of bacterial LeuRS (whose human homologues were named β30_31 and β32_33 (16) comprise most of the residues that are involved in contacts with the elbow region of tRNA
Leu . Thus, we tested the hypothesis that the short peptides from the human enzyme were responsible for the Cterm ability to interact with, and have rescuing activity towards, mutations in human cognate mt-tRNA Leu(UUR) and non-cognate mt-tRNA Lys . The constructs designed for transfection experiments comprise: the mt-targeting sequence (MTS) of human COX8a gene, to ensure mt localization; the nucleotide sequence coding for peptide β30_31, β32_33 or Cterm (as a positive control) and a FLAG domain (for more details see 'Materials and Methods' section).
We transiently overexpressed either β30_31 or β32_33 peptide in cybrid lines, which were subsequently stressed by galactose medium incubation. In these conditions, transformant cells showed: (i) increased viability (up to 1.8-and 1.7-fold for m.3243A>G and m.8344A>G cybrids, respectively, when compared with their mock transformants); and (ii) decreased apoptotic cell death (up to 1.6-and 2-fold for m.3243A>G and m.8344A>G cybrids, respectively, when with to their mock transformants) (Fig. 3A and B) . Conversely, peptide overexpression had no effect on the viability of WT and L-8344 cybrids (Supplementary Material, Fig. S2 ). To investigate whether increased cell viability was actually related to improved mt bioenergetics, we measured oxygen consumption rate in transfected cybrids. Peptide β32_33 increased oxygen consumption in both m.3243A>G and m.8344A>G cybrids, when compared with the respective mock transformants; conversely, peptide β30_31 increased oxygen consumption in m.8344A>G cybrids only (Fig. 3C) .
We verified the transient over-expression of both Cterm and Cterm peptides by real-time PCR for all experiments and by immunofluorescence for a subset of experiments (see the 'Materials and Methods' section). Upon transfection, both peptide and Cterm transformants showed increased mRNA expression levels (Supplementary Material, Fig. S3 ) as well as intense cytoplasmic granular stain with specific anti-FLAG antibodies which was evident in about 50% of transfected cells (Fig. 4A ). In addition, mt localization following transient transfection was verified by using a specific anti-FLAG antibody in combination with Mitotracker Red CMXRos (see Materials and Methods section). As shown in Figure 4B , the peptide-specific immunofluorescence pattern (green) perfectly superimposes the mt network (red).
We also investigated whether transfection with either peptide affected the steady-state levels of mt-tRNA mutants. Highresolution northern blot analysis was performed in WT and m.3243A>G MTTL1 or m.8344A>G MTTK mutant cybrids transiently transfected with peptide β30_31 or β32_33. Values were normalized for 5S rRNA. Consistent with our previous report on m.3243A>G MTTL1 mutant cybrids transfected with the Cterm (9), transient overexpression of either peptide did not result in a significant increase of the mutated mt-tRNA Leu Fig. S4 ), although these changes were at the lower limits of detection for northern experiments. that peptide β32_33 comprises most of the Cterm residues required for cognate mt-tRNA recognition. Interestingly, peptide β32_33 has higher affinity than β30_31 towards non-cognate human mt-tRNA Lys as well (Fig. 5 ). These results suggest that peptides β30_31 and β32_33 might be able to recognize general tRNA features and, therefore, bind additional non-cognate tRNA molecules.
Cterm-derived peptides compensate structure and thermal stability impairments of both human mt-tRNA mutants in vitro Thermal denaturation (TD) experiments were carried out to elucidate whether, and to what extent, the interaction with peptides β30_31 and β32_33 reverts the structure and thermal stability alterations that occur in human mt-tRNA Leu(UUR) and mt-tRNA Lys as a consequence of the m.3243A>G and m.8344A>G mutations, respectively. To this end, tRNAs were synthesized as molecular beacons (MB-tRNAs) with chemical groups able to emit and quench fluorescence at the 5′ and 3′ ends, respectively. In all experiments, low fluorescence was observed at low temperature, due to the vicinity of the 6-carboxyfluorescein (FAM) fluorophore and DABCYL quencher (at 5′ and 3′ end, respectively), and high fluorescence upon thermal melting, due to decreased fluorescence quenching caused by tRNA unfolding. Figure 6A -H shows the results of thermal shift assays (average of three experiments) performed on human MB-mt-tRNA Leu(UUR) WT and m.3243A>G mutant (A-D), and MB-mt-tRNA Lys WT and m.8344A>G mutant (E-H), in the presence of different concentrations of peptide β30_31 or β32_33. Figure 6I reports the values of MB-tRNAs melting temperature (T m ) and percentage of folding at 37% (%Folded 37 ) calculated for each series of experiments. The thermal and structural stability of MB-mt-tRNA Leu(UUR) m.3243A>G mutant are lower than the WT in the absence of peptides (T m = 48°C for both forms but %Folded 37 = 66% for the mutant and 82% for the WT) and increase significantly upon addition of peptide β30_31 and β32_33 up to 2 µ. Consistent with the results of tRNA-binding affinity, peptide β32_33 has the highest stabilization effect (T m increases by 4°C versus 1°C and %Folded 37 increases by 8 versus 5%). As expected, WT MB-mt-tRNA Leu(UUR) undergoes only small changes in thermal and structural stability in the presence of peptide β30_31 up to 3 µ and β32_33 up to 2 µ (see Fig. 6 ). Intriguingly, the structures of MB-mt-tRNA Lys (WT and m.8344A>G mutant) are slightly stabilized by peptide β30_31 but not by the addition of peptide β32_33. 
Discussion
In the present study, we expand recent results previously reported by our group and others about the ability of human mtLeuRS Cterm to interact with both cognate and non-cognate mt-tRNAs, and rescue pathological phenotypes arising from mt-tRNA mutations in human cells (9, 10) . While the Cterm had been shown to interact with a number of non-cognate mttRNAs aminoacylated by both class I and II aminoacyl-tRNA synthetases (aaRSs) (10), its rescuing ability had been demonstrated only towards mt-tRNAs aminoacylated by aaRSs belonging, like LeuRS, to class Ia (9). Since aaRSs belonging to the same class and subclass have higher structure and sequence similarity to one another than to other aaRSs, whether the therapeutic properties of the Cterm could be extended to mutations in mt-tRNAs aminoacylated by aaRSs other than those in class Ia remained an open question. Here, we show that, remarkably, the Cterm is able to ameliorate the phenotype of cybrid cells carrying the m.8344A>G mutation in mt-tRNA Lys , which has the following features: (i) the cognate LysRS belongs to class II and thus is not evolutionarily related to class I enzymes; (ii) it is one of the most prevalent among disease-causing mt-tRNA mutations; (iii) it is responsible for a severe syndrome (MERRF). Together with recent observations in yeast (16, 17) , these results strongly support the hypothesis that the Cterm may rescue defects due to mutations in a number of additional mt-tRNAs aminoacylated by aaRSs belonging to both classes. This makes the Cterm a promising candidate as 'universal suppressor' for mt-tRNA mutation-associated diseases. Importantly, we demonstrate here that not only LeuRS C-terminal domain but also two short peptides derived from it, β30_31 and β32_33, are endowed with rescuing ability towards two mutations: m.3243A>G in mt-tRNA Leu(UUR) and m.8344A>G in mt-tRNA Lys . The ability of both peptides to rescue pathological phenotypes due to mutations in a number of mt-tRNAs, which are aminoacylated by aaRSs belonging to different classes and subclasses, has been recently suggested in yeast (17) . Our results on the activities of peptides β30_31 and β32_33, together with the overall LeuRS sequence conservation from eukaryote mitochondria to bacterial cells indicate that, in spite of the evolutionary distance and different cellular compartment, the modality of tRNA recognition and regions involved in tRNA binding are largely conserved.
The overall rescuing activity of peptides β30_31 and β32_33 is manifested by increased cell viability and decreased apoptotic cell death, as is the case with the Cterm (9). Intriguingly, while peptide β32_33 restores oxygen consumption of both mutant cybrids, upon transfection with peptide β30_31 this effect is observed only in m.8344A>G cybrids, suggesting a different effect of this peptide on the respiratory chain function affected by either mutation.
Despite the significant increase in cell viability, we did not detect an increase of either mutant mt-tRNA Leu(UUR) or mttRNA Lys steady-state levels upon transient overexpression of either peptide β30_31 or β32_33. These results are in line with our previous observations on m.3243A>G cybrids transiently transfected with the Cterm (9) and suggest that, in agreement with our hypothesis of a chaperonic mechanism of action, the effect of our molecules is mainly to improve the function of the mutant mt-tRNAs, rather than preventing them from degradation. On the other hand, we observed a slight, albeit significant increase of mutant mt-tRNA Leu(UUR) steady-state levels after stable transfection of m.3243A>G cybrids with the Cterm. Thus, on a longer timescale an effect on mutant mt-tRNA steady state levels can be highlighted, which may contribute to the rescuing activity.
The results of our in vitro experiments contribute to elucidate the molecular basis of the rescuing activity of peptides β30_31 and β32_33 and support the hypothesis that they act as molecular chaperones, as previously proposed for the Cterm. In fact, in spite of their small size, the two peptides were able to bind directly and with high affinity to all WT and mutant mt-tRNAs investigated in this work. These results suggest that peptide-tRNA interactions are mediated by structural features shared by tRNA molecules, consistent with the rationale behind peptide design. Accordingly, both peptides bind WT mt-tRNAs with higher affinity than their mutant counterparts, the structure of which is affected by the presence of the mutation. Peptide β32_33 showed a significantly higher binding affinity than peptide β30_31 towards each and all of the investigated tRNA forms, indicating that it is a better candidate for future therapeutic applications.
To investigate the effects of peptide binding on the mt-tRNA structure and stability, we performed thermal melting experiments on tRNAs modified to act as MB-tRNAs. These experiments highlighted that the m.3243A>G mutation induces a thermal and structural destabilization of mt-tRNA Leu(UUR) , both of which are reversed by association with peptide β32_33 and, to a lesser extent, β30_31. These results support the hypothesis that the two peptides act like molecular chaperones, by stabilizing a mt-tRNA Leu(UUR) conformation suitable to establish interactions with partner molecules (e.g. aaRSs, elongation factors, ribosome, mRNAs etc.) that are required to enact tRNA function. In addition, the mutation-dependent dimerization of mt-tRNA Leu (UUR) m.3243A>G, which may contribute to impairment of the tRNA function, is substantially decreased by the interaction with peptides β30_31 and β32_33 (Supplementary Material, Fig. S5 ). Conversely, we could not detect a significant increase in either thermal stability or folding of the mt-tRNA Lys m.8344A>G mutant, despite the ability of both peptides to directly interact with both WT and mutant tRNA Lys with high affinity. This result may be ascribed to the absence of post-transcriptional modifications in the in vitro synthesized WT and mutant mt-tRNA Lys used in our experiment, since editing has been proposed to play an important role in the stabilization of a canonical two-dimensional and 3D mt-tRNA Lys structure (20, 21) . Alternatively, in the case of the mt-tRNA Lys mutant the rescuing effect of the peptides may be mediated by a non-chaperonic mechanism, consisting, for example, in the protection from degradation. Although we cannot exclude that the effect of β32_33 peptide on mt-tRNA Lys stability depends on peptide binding to regions different from those recognized in 'cognate' mt-tRNA Leu(UUR) , the ability of the β32_33
peptide to rescue defects due to mutations in a large panel of mt-tRNA mutants previously demonstrated in yeast (17) supports the hypothesis that common structural features of tRNA molecules are at least partially involved in the interaction.
In conclusion, we provide evidence that small peptides derived from the mt-LeuRS Cterm can be effective tools to rescue cellular defects caused by mutations in mt-tRNAs. As a consequence, these peptides represent an important advance in the quest for therapeutic agents against diseases caused by mutations in mt-tRNAs. The whole Cterm is amenable to gene therapy-based approaches [see for example (22, 23) ], whilse small peptides could be more directly administered, possibly aided by suitable carrier molecules and/or mitochondria-targeting agents. Additionally, small peptides may serve as a basis for the development of non-peptide synthetic compounds, particularly if the rescuing activity can be mapped to even smaller peptide regions. Strikingly, the ability of the peptide to rescue defects due to mutations in 'non-cognate' in addition to 'cognate' mt-tRNAs suggests that they may be used to develop wide-spectrum therapeutics towards mt-tRNA mutation-associated diseases.
Materials and Methods

Cybrid cell lines
For this study, we used previously established osteosarcoma-derived (143B.TK Table S1 ). The m.8344A>G cybrids were established in Valeria Tiranti's laboratory as previously described (26) . We then manipulated the ratio of mutant and WT mt-DNA of the m.8344A>G cybrids using EtBr. Cybrid cells were maintained in glucose medium supplemented with 20 ng/ml of EtBr for 10 days as previously described (27) and replated to repopulate mitochondria at low density in glucose medium. Individual cell clones (∼50) were isolated 10-20 days later using glass cylinders and tested for the mutation load. For the present study, we selected two clones, showing high (86%) and low (34%) levels of m.8344A>G mutation, respectively.
Assessment of m.8344 A>G mutation load
Accurate m.8344A>G heteroplasmy levels were obtained by quantitative pyrosequencing using a Pyromark Q24 platform. The PyroMark assay design software v2.0 (Qiagen, Hilden, Germany) and the current mtDNA reference sequence (Genbank accession number: NC_012920.1) were used to design mutation-specific pyrosequencing primer trios [5′biotinylated forward: m. 8240-8264; reverse: m. 8364-8387 and reverse pyrosequencing primer: m.8348-8367 (IDT, Coralville, IA, USA)]. The allele quantification application of the proprietary Q24 software was used to calculate mtDNA heteroplasmy levels using standard parameters.
Cell culture
Cybrid cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 4.5 g/l d-glucose, 10% fetal bovine serum (FBS), 2 m l-glutamine, 50 µg/ml uridine, 100 U/ml penicillin and 100 mg/ml streptomycin (referred to as glucose medium) in a humidified atmosphere of 95% air and 5% CO 2 at 37°C. For a subset of experiments cybrids were grown in glucose-free DMEM, supplemented with 5 m galactose, 110 mg/ml sodium pyruvate and 10% FBS (referred as galactose medium).
Bioinformatics analysis
Structure visualization and analysis were performed using PyMol (http://www.pymol.org/). Cterm residues interacting with tRNA Leu in experimentally determined 3D structures (14, 15) were calculated using the FACE2FACE server developed by the authors (http://apps.ibpm.cnr.it/f2f/index). The multiple sequence alignment shown in Figure 2C was obtained by merging the alignments of human and yeast mt-LeuRS to LeuRS from T. thermophilus and E. coli obtained using Phyre2 (28) .
Plasmid construction
Cybrid cells were transiently transfected with either the C-terminal region of human mt-LeuRS (named pCterm) or the short peptides derived from it (named pβ30_31 and pβ32_33) cloned into pcDNA3.2-TOPO vector (Invitrogen™, Life Technologies Italia, MB, Italy). The cDNA fragments (listed in Supplementary Material, Table S2 ) were fused at 5′ with the mitochondrial-targeting sequence (MTS) derived from human COX8 gene (29) and at 3′ with the FLAG sequence (5′-GATTACAAGGATGACGACGATAAG-3′). Both the MTS and the FLAG sequences were separated from the peptide sequence by a 5-residue linker (GGSGG).
Transient and stable transfections
Cybrids were plated in 60 mm dishes, incubated in glucose medium for 24 h, and then transfected with 2.5 µg of the full or empty vector (mock) by using LIPOFECTINE 3000 (Life Technologies Italia), according to the manufacturer's protocol. Stable clones were selected and maintained in glucose medium supplemented with G418 (300 µg/ml). Prior to testing the effect of our constructs, we verified that the mutation load of m.3243A>G and m.8344A>G mutant cybrids did not change upon transfection (Supplementary Material, Fig. S6 ). To assess m.3243A>G mutation load we used the assay previously described by McDonnel et al. (30) . Briefly, WT 154 base-pairs (bps) PCR products amplified with forward (5′-TATACCCACACCCACCCAA-3′) and reverse (5′-GCGATTAGAATGGGTACAAT −3′) primers contain a single HaeIII restriction site, which cleaves the amplicons into two fragments of 117 and 37 bps. The m.3243A>G mutation introduces a second HaeIII recognition site that cuts the 117 bps fragment into two smaller fragments of 72 and 45 bps. To assess m.8344A>G mutation load, we used the assay previously described by Larsson et al. (31) . Briefly, WT 230 bps PCR products, amplified with forward (5′-CTACGGTCAATGCTCTGAAA-3′) and reverse (5′-ATA CGGTAGTATTTAGTTGGGGCATTTCACTGTAAAGCCGTGTTGG-3′) mismatch primers, do not contain any BglI restriction site. The m.8344A>G mutation introduces a BglI recognition site that cuts the 230 bps fragment into two smaller fragments of 184 and 46 bps. Restriction fragments were separated and identified using the Agilent 2100 bioanalyzer instrument with the 1000 Lab Chip kit (Supplementary Material, Fig. S6 ).
Evaluation of transient transfection efficiency by real-time PCR
About 24 h after transfection total RNA was isolated, measured and reverse-transcribed to cDNA as previously described (9) . To assess the relative expression of MTS-Cterm-FLAGwe used TaqMan probe chemistry by means of custom FAM-labelled TaqMan MGB probe (Applied Biosystems Warrington, UK; Supplementary Material, Table S3 ), according to the manufacturer's instructions. In all samples, the relative expression of the target gene was evaluated with respect to the average of controls (mock sample) using the comparative threshold cycle (ΔC t ) method. All values were normalized for the housekeeper 18S ribosomal RNA (18S) using inventoried FAM-labelled TaqMan MGB probes (Supplementary Material, Table S3 ). Due to the shortness of Cterm-peptides the primers of the real-time PCR assays were design to anneal, respectively, with the MTS and the FLAG sequence (Supplementary Material, Table S3 ). These assays prevented the normalization of over-expressed β30_31 and β32_33 relative to the endogenous levels of mt-LeuRS in the mock.
Evaluation of constructs expression levels by immunofluorescence
About 24 h after transfection cells were fixed with 4% formaldehyde freshly prepared from paraformaldehyde in phosphate buffered saline (PBS) ( pH 7.4) with 0.1% Triton X-100. Mouse monoclonal anti-FLAG (Sigma, Saint Louis, MO, USA) was used as primary antibody and visualized using secondary fluorescein isothiocyanate-conjugated antibody (Jackson Laboratories, Bar Harbor, ME, USA). Cells were examined and imaged with an Olympus IX50 Fluorescence microscope.
Mt localization of constructs
About 24 h after transfection cells were incubated with 100 nm Mitotracker red CMXRos (Life Technologies Italia) for 20 min at 37°C and then fixed with 4% formaldehyde freshly prepared from paraformaldehyde in PBS ( pH 7.4) for 15 min at 37°C. Subsequently cells were incubated with mouse monoclonal anti-FLAG (Sigma) and visualized by mean of secondary Alexa fluor goat anti-mouse 488 (Life Technologies Italia).
Cell proliferation assay
To test growth capability, transformed cells were maintained in glucose medium for 24 h and then harvested and seeded at 30 × 10 4 in 60 mm dishes in glucose or galactose. Cell viability was measured by the Trypan blue dye exclusion assay. Cells were harvested after 24 h with 0.25% trypsin and 0.2% ethylenediaminetetraacetic acid, washed, suspended in PBS in the presence of Trypan blue solution (Sigma) at 1:1 ratio, and counted using a haemocytometer. The number of viable cells in galactose medium was expressed as a percentage of the number of cells in glucose medium.
Rate of apoptosis by flow cytometer
To test the rate of apoptosis transformed cells were maintained in glucose medium for 24 h and then harvested and seeded at 0. 
Respirometry assay
Oxygen consumption rate (OCR) of transfected cybrids was evaluated with Clark type oxygen electrode (Hansatech Instruments, Norfolk UK). After transfection control and mutant cybrids were maintained in glucose medium for 48 h, then OCR was measured in intact cells (3 × 10 6 ) in 1 ml DMEM lacking glucose supplemented with 10% sodium pyruvate, as previously described (33) .
High-resolution northern
To determine mt-tRNA Leu 
SPR experiments
SPR experiments were carried out with a SensiQ Pioneer apparatus. N-biotinylated β30_31 and β32_33 peptides (see Fig. 2 ) were synthesized by Biomatik ( purity > 90%). Streptavidin-coated BioCap sensorchips were chemically activated by a 35 µl injection of 10 m NaOH at 10 µl/min flow rate. N-biotinylated peptides were immobilized via interaction with the streptavidin surface of the chips. This procedure ensured directional immobilization of the peptides. The amount of immobilized peptides was detected by mass concentration-dependent changes in the refractive index on the sensor chip surface, and corresponded to ∼50 resonance units (RU As a negative control, sensor chips were treated as described above in the absence of immobilized N-biotinylated peptides. Values of the plateau signal at steady-state (R eq ) were calculated from kinetic evaluation of the sensorgrams using the Qdat 4.0 programme. The equilibrium constant of ligand-analyte interaction was evaluated by Scatchard analysis of the dependence of R eq on analyte concentration.
TD experiments on tRNA-MBs
Samples of human WT mt-tRNA Leu(UUR) , mt-tRNA Leu(UUR) m.3243A>G, WT mt-tRNA Lys and mt-tRNA Lys m.8344A>G were synthesized by Trilink Biotechnologies. All tRNAs used for TD experiments were synthesized as MB-tRNAs by using a 3′-DABCYL support for tRNA synthesis, and 5′ FAM modification was added using phosphoramidite chemistry. Dual polyacrylamide gel electrophoresis/high-pressure (or high-performance) liquid chromatography purification was performed for all samples, followed by a desalting step and subsequent lyophilization of the final compound. For all tested samples, purity was >95%. β30_31 and β32_33 peptides were synthesized by Biomatik ( purity > 90%). TD experiments were performed with a Mx3000P Real-Time PCR System (Stratagene, La Jolla, CA, USA) in PCR-96-microplates, using 25 µl sample volume, 0.14 µ MB-tRNAs in 20 m HEPES pH 7.4 + 150 m NaCl + 1 m MgCl 2 + 0.1 m spermine (Spm), and different concentrations of β30_31 or β32_33 peptide. At least two experiments were performed for each condition, and triplicate samples were used within the same experiment. Sample temperature was increased from 25 to 90°C at 0.5°C/min rate. Fluorescence was measured at each temperature step (0.5°C) using FAM filter set (excitation: 492 nm, emission: 516 nm). As negative controls we used sample wells with 20 m HEPES pH 7.4 + 150 m NaCl + 1 m MgCl 2 + 0.1 m spermine alone or in the presence of either MBtRNA or different concentration of β30_31 or β32_33 peptide.
Normalized 
Gel electrophoresis
Statistical analysis
All data are expressed as mean ± SEM. Data were analysed by standard paired t-test procedures. The significance was considered at P < 0.05. Numerical estimates were obtained with the Graphpad InStat 3 version (Graphpad, Inc., San Diego, CA, USA).
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